Search

Search Constraints

You searched for: Author/Creator McDermott, Ray

Search Results

1. 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial. (3rd August 2022)

3. A Multicenter Retrospective Review of Systemic Anti-Cancer Treatment and Palliative Care Provided to Solid Tumor Oncology Patients in the 12 Weeks Preceding Death in Ireland. (December 2021)

5. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Issue 10336 (30th April 2022)

8. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Issue 6 (29th April 2022)